The PAREXEL BioPharm Unit provides the defined expertise, global infrastructure, operational excellence and technologies needed to help small biopharmaceutical companies advance their drugs through the development cycle.
The new delivery model provides customized solution that results in accelerated development timelines, reduced cost and a high level of quality.
PAREXEL BioPharm Services vice president Ubavka DeNoble said the small and mid-sized biopharmaceutical companies are the genesis of innovation.
"The creation of the PAREXEL BioPharm Unit is especially important for small pharma and biotech sponsors that have needs that are meaningfully different from large pharma sponsors," DeNoble added.
"The breadth and depth of our expertise gives us the ability to create customized solutions that are designed to meet the particular needs of each client — whether the company is a small research venture, a growing mid-sized business, or a global enterprise."
PAREXEL’s BioPharm Unit provides companies the opportunity to accelerate patient recruitment, increase the speed of study start-up, shorten time to database lock, and improve overall efficiency for meeting critical development milestones.